Obesity Clinical Trials in New York

Showing 121-122 of 122 trials

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

NCT00481975

The primary objective is to assess the effect of rimonabant compared to placebo on weight loss over a period of 6 months when prescribed with a mild hypocaloric diet in obese patients with binge eating disorder. The secondary objectives are: * to assess the effect of rimonabant on the number of binge episodes per week, to assess the effect of rimonabant on eating behavior using the Binge Eating Scale (BES) and Three Factor Eating Questionnaire (TFEQ), * to evaluate the safety and tolerability of rimonabant over a period of 6 months.

ObesityEating Disorders

Sanofi289 participantsStarted Aug 2004

Bridgewater, New Jersey, United States • Helsinki, Finland • Paris, France +4 more locations

UNKNOWNPHASE21195 miles

Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)

NCT00449202

The purpose of this study is to evaluate the safety, preliminary efficacy, and pharmacokinetics of two 14-day cycles of escalating oral doses of MP 101 in 100 obese adult subjects.

Obesity

Manhattan Pharmaceuticals100 participantsStarted Jun 2006

Baton Rouge, Louisiana, United States • Salt Lake City, Utah, United States • Basel, Switzerland

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)

Obesity Trials in Other Cities

Other Conditions in New York